Efonidipine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Efonidipine
Accession Number
DB09235
Type
Small Molecule
Groups
Approved
Description

Efonidipine (INN) is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel. The drug blocks both T-type and L-type calcium channels. It has also been studied in atherosclerosis and acute renal failure.

Structure
Thumb
Synonyms
Not Available
External IDs
NZ-105
Product Ingredients
IngredientUNIICASInChI Key
Efonidipine hydrochloride3BR983K69O111011-53-1OXVTXPCIJDYQIS-UHFFFAOYSA-N
International/Other Brands
Landel (Shionogi & Co.)
Categories
UNII
40ZTP2T37Q
CAS number
111011-63-3
Weight
Average: 631.666
Monoisotopic: 631.244737574
Chemical Formula
C34H38N3O7P
InChI Key
NSVFSAJIGAJDMR-UHFFFAOYSA-N
InChI
InChI=1S/C34H38N3O7P/c1-24-30(33(38)42-19-18-36(28-15-9-6-10-16-28)21-26-12-7-5-8-13-26)31(27-14-11-17-29(20-27)37(39)40)32(25(2)35-24)45(41)43-22-34(3,4)23-44-45/h5-17,20,31,35H,18-19,21-23H2,1-4H3
IUPAC Name
2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2λ⁵-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
SMILES
CC1=C(C(C2=CC=CC(=C2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(CC1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of hypertension.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Efonidipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Efonidipine.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Efonidipine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Efonidipine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Aldesleukin.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Efonidipine.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Efonidipine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Efonidipine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Efonidipine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Efonidipine.Illicit
AlprenololAlprenolol may increase the hypotensive activities of Efonidipine.Approved, Withdrawn
AmbrisentanEfonidipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineEfonidipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Efonidipine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Efonidipine.Approved
AmobarbitalThe metabolism of Efonidipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Efonidipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Efonidipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Efonidipine is combined with Amyl Nitrite.Approved
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Efonidipine.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Efonidipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Efonidipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Efonidipine.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Efonidipine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Efonidipine.Approved
AtenololAtenolol may increase the hypotensive activities of Efonidipine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Efonidipine is combined with Atosiban.Approved
Atracurium besylateEfonidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Efonidipine is combined with Azilsartan medoxomil.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Efonidipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Efonidipine.Experimental
BarbitalThe metabolism of Efonidipine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Efonidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Efonidipine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Efonidipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Efonidipine.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Efonidipine.Approved
BepridilBepridil may increase the hypotensive activities of Efonidipine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Efonidipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Efonidipine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Efonidipine.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Efonidipine.Experimental
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Efonidipine.Approved
BimatoprostBimatoprost may increase the hypotensive activities of Efonidipine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Efonidipine.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Efonidipine.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Efonidipine.Approved, Investigational
BQ-123Efonidipine may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when 1,6,7,8,9,11A,12,13,14,14A-DECAHYDRO-1,13-DIHYDROXY-6-METHYL-4H-CYCLOPENT[F]OXACYCLOTRIDECIN-4-ONE is combined with Efonidipine.Experimental
BretyliumBretylium may increase the hypotensive activities of Efonidipine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Efonidipine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Efonidipine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Efonidipine.Approved, Investigational
BucindololBucindolol may increase the hypotensive activities of Efonidipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Bumetanide.Approved
BunazosinBunazosin may increase the hypotensive activities of Efonidipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Efonidipine.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Efonidipine.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Efonidipine.Approved, Illicit, Investigational, Vet Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Efonidipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Efonidipine.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Efonidipine.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Efonidipine.Experimental
CafedrineEfonidipine may increase the hypotensive activities of Cafedrine.Investigational
CalciumThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium CitrateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Canagliflozin.Approved
CandesartanCandesartan may increase the hypotensive activities of Efonidipine.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Efonidipine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Efonidipine.Experimental
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Efonidipine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Efonidipine.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Efonidipine.Approved
CarbomycinThe metabolism of Efonidipine can be decreased when combined with Carbomycin.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Efonidipine.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Efonidipine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Efonidipine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Efonidipine.Approved, Investigational
CaseinThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Efonidipine.Approved
CeliprololCeliprolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
CerivastatinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Efonidipine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Efonidipine.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Efonidipine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Efonidipine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Efonidipine.Approved
CicletanineEfonidipine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Efonidipine.Approved, Investigational
CilazaprilCilazapril may increase the hypotensive activities of Efonidipine.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Efonidipine.Approved
CimetidineThe serum concentration of Efonidipine can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Efonidipine can be decreased when combined with Clarithromycin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Efonidipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Efonidipine.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Efonidipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Efonidipine.Approved, Nutraceutical
CloranololEfonidipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Efonidipine.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Efonidipine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Efonidipine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Efonidipine.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Efonidipine.Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Efonidipine.Approved
CyclopenthiazideEfonidipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Efonidipine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Efonidipine.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Efonidipine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Efonidipine.Approved
DelaprilEfonidipine may increase the hypotensive activities of Delapril.Experimental
DeserpidineEfonidipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Efonidipine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Efonidipine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Efonidipine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Efonidipine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Efonidipine.Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Efonidipine.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Diclofenamide.Approved
diethylnorsperminediethylnorspermine may increase the hypotensive activities of Efonidipine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Efonidipine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Efonidipine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Efonidipine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Efonidipine.Experimental, Illicit
DiltiazemDiltiazem may increase the hypotensive activities of Efonidipine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Efonidipine is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Efonidipine.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Efonidipine is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Efonidipine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Efonidipine.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Efonidipine.Investigational
DuloxetineEfonidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Efonidipine.Approved
EfavirenzThe serum concentration of Efonidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Efonidipine.Approved, Vet Approved
EnalaprilatEfonidipine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Efonidipine.Experimental
EpanololEfonidipine may increase the hypotensive activities of Epanolol.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Eplerenone.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Efonidipine.Approved
EprosartanEprosartan may increase the hypotensive activities of Efonidipine.Approved
ErythromycinThe metabolism of Efonidipine can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Efonidipine is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Efonidipine is combined with Etacrynic acid.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Efonidipine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Efonidipine.Illicit, Vet Approved
FelodipineFelodipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Efonidipine.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Efonidipine.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Efonidipine.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Efonidipine.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Efonidipine is combined with Fimasartan.Approved
FluconazoleThe serum concentration of Efonidipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Efonidipine.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Efonidipine.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Fluvastatin.Approved
FosinoprilFosinopril may increase the hypotensive activities of Efonidipine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Efonidipine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Efonidipine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Furosemide.Approved, Vet Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Efonidipine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Efonidipine.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Efonidipine.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Efonidipine.Approved
GuanazodineEfonidipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Efonidipine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Efonidipine.Approved, Investigational
GuanoclorEfonidipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzEfonidipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanEfonidipine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Efonidipine.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Efonidipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Efonidipine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Efonidipine.Approved, Illicit
HexamethoniumHexamethonium may increase the hypotensive activities of Efonidipine.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Efonidipine.Approved
HexobarbitalThe metabolism of Efonidipine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Efonidipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Efonidipine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Efonidipine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Efonidipine.Approved, Illicit
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Efonidipine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Efonidipine.Approved, Illicit
IloprostIloprost may increase the hypotensive activities of Efonidipine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Efonidipine is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Imipramine.Approved
IndapamideIndapamide may increase the hypotensive activities of Efonidipine.Approved
IndenololIndenolol may increase the hypotensive activities of Efonidipine.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Efonidipine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Efonidipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Efonidipine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Efonidipine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Efonidipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Efonidipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Efonidipine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Efonidipine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Efonidipine.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Efonidipine.Approved, Investigational
JosamycinThe metabolism of Efonidipine can be decreased when combined with Josamycin.Approved
KetanserinKetanserin may increase the hypotensive activities of Efonidipine.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Efonidipine.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Efonidipine.Approved, Investigational
KitasamycinThe metabolism of Efonidipine can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Efonidipine.Approved
LacidipineEfonidipine may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Efonidipine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Efonidipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Levobupivacaine.Approved
LevodopaEfonidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Efonidipine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Efonidipine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Efonidipine is combined with Levosimendan.Approved, Investigational
LinsidomineEfonidipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Efonidipine.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Efonidipine.Illicit
LofexidineLofexidine may increase the hypotensive activities of Efonidipine.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Efonidipine.Approved
LovastatinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Lovastatin.Approved, Investigational
MacitentanEfonidipine may increase the hypotensive activities of Macitentan.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Efonidipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Efonidipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineEfonidipine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Efonidipine is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Efonidipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Efonidipine.Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Efonidipine.Experimental
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Efonidipine.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Efonidipine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Efonidipine.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Methazolamide.Approved
MethohexitalThe metabolism of Efonidipine can be increased when combined with Methohexital.Approved
MethoserpidineEfonidipine may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Methyclothiazide.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Efonidipine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Efonidipine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Efonidipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Efonidipine can be increased when combined with Methylphenobarbital.Approved
MetipranololMetipranolol may increase the hypotensive activities of Efonidipine.Approved
MetolazoneMetolazone may increase the hypotensive activities of Efonidipine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
MetyrosineEfonidipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Efonidipine.Experimental
MibefradilMibefradil may increase the hypotensive activities of Efonidipine.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Efonidipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Efonidipine.Approved, Investigational, Vet Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Efonidipine.Approved
MinaprineMinaprine may increase the hypotensive activities of Efonidipine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Efonidipine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Efonidipine.Investigational
MivacuriumEfonidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Efonidipine.Approved
MoexiprilMoexipril may increase the hypotensive activities of Efonidipine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Efonidipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Efonidipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Efonidipine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Efonidipine.Approved
MuzolimineEfonidipine may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Efonidipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nabilone.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Efonidipine.Approved
NafcillinThe metabolism of Efonidipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Efonidipine.Approved
NaftopidilEfonidipine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Efonidipine.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Efonidipine.Approved
NebivololNebivolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Efonidipine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Efonidipine.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Efonidipine.Experimental
NicorandilNicorandil may increase the hypotensive activities of Efonidipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nifedipine.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Efonidipine.Experimental
NiguldipineEfonidipine may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Efonidipine.Investigational
NilvadipineNilvadipine may increase the hypotensive activities of Efonidipine.Approved
NimodipineNimodipine may increase the hypotensive activities of Efonidipine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Efonidipine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Efonidipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideEfonidipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Efonidipine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Efonidipine.Approved, Illicit
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Efonidipine.Approved, Vet Approved
ObinutuzumabEfonidipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Efonidipine.Withdrawn
OleandomycinThe metabolism of Efonidipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanOlmesartan may increase the hypotensive activities of Efonidipine.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Efonidipine.Investigational
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Efonidipine.Experimental
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Efonidipine.Approved, Illicit
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Efonidipine.Approved
OxprenololOxprenolol may increase the hypotensive activities of Efonidipine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Efonidipine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Efonidipine.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Efonidipine is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Efonidipine.Investigational
PapaverineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Efonidipine.Approved
PenbutololPenbutolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Efonidipine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Efonidipine.Approved, Vet Approved
PentobarbitalThe metabolism of Efonidipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Efonidipine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Efonidipine.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Efonidipine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Efonidipine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Efonidipine.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Efonidipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Efonidipine.Withdrawn
PhenobarbitalThe metabolism of Efonidipine can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Efonidipine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Efonidipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Efonidipine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Efonidipine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Efonidipine.Approved, Vet Approved
PinacidilPinacidil may increase the hypotensive activities of Efonidipine.Withdrawn
PindololPindolol may increase the hypotensive activities of Efonidipine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Pipamperone.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Efonidipine.Investigational
PirlindolePirlindole may increase the hypotensive activities of Efonidipine.Approved
PitavastatinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Pitavastatin.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Efonidipine.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Efonidipine.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Efonidipine.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Efonidipine is combined with Pramipexole.Approved, Investigational
PravastatinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Efonidipine.Approved
PrimidoneThe metabolism of Efonidipine can be increased when combined with Primidone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Efonidipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Efonidipine.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Efonidipine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Efonidipine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Efonidipine.Experimental
RamiprilRamipril may increase the hypotensive activities of Efonidipine.Approved
RapacuroniumEfonidipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Efonidipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Efonidipine.Approved
RemikirenRemikiren may increase the hypotensive activities of Efonidipine.Approved
RescinnamineEfonidipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Efonidipine.Approved
RifabutinThe serum concentration of Efonidipine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Efonidipine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Efonidipine can be decreased when it is combined with Rifapentine.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Efonidipine.Investigational
RiociguatEfonidipine may increase the hypotensive activities of Riociguat.Approved
RisperidoneEfonidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabEfonidipine may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Efonidipine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Ropivacaine.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Rosuvastatin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Efonidipine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Efonidipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Efonidipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Efonidipine.Approved, Vet Approved
SaprisartanSaprisartan may increase the hypotensive activities of Efonidipine.Experimental
SecobarbitalThe metabolism of Efonidipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Efonidipine.Approved, Investigational, Vet Approved
SelexipagEfonidipine may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Efonidipine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Efonidipine.Approved, Investigational
SilodosinSilodosin may increase the hypotensive activities of Efonidipine.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Efonidipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Efonidipine.Approved, Investigational
SitaxentanEfonidipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Efonidipine is combined with Sodium Nitrite.Approved
Sodium phosphateEfonidipine may increase the nephrotoxic activities of Sodium phosphate.Approved
SolithromycinThe metabolism of Efonidipine can be decreased when combined with Solithromycin.Investigational
SotalolThe risk or severity of adverse effects can be increased when Efonidipine is combined with Sotalol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Efonidipine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Efonidipine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Efonidipine.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Efonidipine.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Efonidipine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Efonidipine.Approved, Investigational
TalinololEfonidipine may increase the hypotensive activities of Talinolol.Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Efonidipine.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Efonidipine.Approved
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Efonidipine.Approved
TelithromycinThe metabolism of Efonidipine can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Efonidipine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Efonidipine.Experimental, Investigational
TerazosinTerazosin may increase the hypotensive activities of Efonidipine.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Efonidipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Efonidipine.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Efonidipine.Approved, Investigational
TetrahydropalmatineEfonidipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Efonidipine is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineEfonidipine may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe metabolism of Efonidipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Efonidipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Thioridazine.Withdrawn
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Efonidipine.Approved
TiboloneTibolone may increase the hypotensive activities of Efonidipine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Efonidipine.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Efonidipine.Experimental
TimololTimolol may increase the hypotensive activities of Efonidipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Efonidipine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Tizanidine.Approved
TolazolineTolazoline may increase the hypotensive activities of Efonidipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Efonidipine is combined with Tolcapone.Approved, Withdrawn
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Efonidipine.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Efonidipine.Approved, Vet Approved
TolonidineEfonidipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Efonidipine.Approved
TorasemideTorasemide may increase the hypotensive activities of Efonidipine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Efonidipine.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Efonidipine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Efonidipine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Efonidipine.Approved
TravoprostTravoprost may increase the hypotensive activities of Efonidipine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Efonidipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Efonidipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Triamterene.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Efonidipine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Efonidipine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Efonidipine.Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Efonidipine.Approved, Investigational
TylosinThe metabolism of Efonidipine can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Efonidipine is combined with Ubidecarenone.Experimental
UdenafilUdenafil may increase the antihypertensive activities of Efonidipine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Efonidipine.Approved
UrapidilUrapidil may increase the hypotensive activities of Efonidipine.Investigational
ValsartanValsartan may increase the hypotensive activities of Efonidipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Efonidipine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Efonidipine is combined with Verapamil.Approved
VincamineEfonidipine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineEfonidipine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Efonidipine.Approved, Investigational
XipamideEfonidipine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Efonidipine.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Efonidipine.Approved, Vet Approved
ZofenoprilEfonidipine may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

General References
  1. Tanaka H, Shigenobu K: Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels. Cardiovasc Drug Rev. 2002 Winter;20(1):81-92. [PubMed:12070536]
External Links
PubChem Compound
119171
PubChem Substance
310265139
ChemSpider
106463
ChEBI
135859
ChEMBL
CHEMBL2074922

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableRecruitingBasic ScienceEndothelium, Vascular1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000248 mg/mLALOGPS
logP5.35ALOGPS
logP5.44ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)19.49ChemAxon
pKa (Strongest Basic)2.33ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area120.24 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity175.4 m3·mol-1ChemAxon
Polarizability64.96 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylbenzamines. These are aromatic compounds consisting of a benzyl group that is N-linked to a benzamine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylmethylamines
Direct Parent
Phenylbenzamines
Alternative Parents
Dihydropyridinecarboxylic acids and derivatives / Nitrobenzenes / Aniline and substituted anilines / Benzylamines / Dialkylarylamines / Nitroaromatic compounds / Phosphonic acid diesters / Aralkylamines / Phosphonic acid esters / Vinylogous amides
show 15 more
Substituents
Phenylbenzamine / Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Benzylamine / Nitroaromatic compound / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Aniline or substituted anilines / Dihydropyridine / Phosphonic acid diester
show 36 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 10:29 / Updated on October 02, 2017 06:14